Annual report highlights 2012 cancer advances
The American Society of Clinical Oncology has released a nearly 100-page report detailing the year’s most significant developments in cancer.
Diagnosis & Disease Information
Regorafenib prolongs survival in face of GI cancers
Persons with metastatic colorectal cancer or gastrointestinal stromal tumors may garner some survival benefit from regorafenib after standard treatments have failed.
Patient preference doesn’t affect chemo in advanced CRC
Most advanced colorectal cancer patients receive chemotherapy even if they doubt the benefits.
FDA Update – July/August 2012
News about pertuzumab injection (Perjeta); ondansetron (Zofran); carfilzomib (Kyprolis); Therascreen KRAS RGQ PCR Kit; Prostate Health Index (phi); and Prepopik
Metastatic Colorectal Cancer and KRAS Gene Testing
Patients with metastatic colorectal cancer can use this fact sheet to learn more about personalized medicine and KRAS gene testing.
Cancer of the appendix differs from colorectal cancer after all
Gene expression profiling has demonstrated that appendiceal cancer is quite distinct from colorectal cancer and may require different treatment.
Two approaches recommended to reduce oxaliplatin toxicity during colorectal therapy
A review addresses the need to balance the effectiveness of oxaliplatin against its dose-limiting complication of neurotoxicity.
Experimental agent slows progression of colorectal cancer
The investigational drug regorafenib conferred a statistically significant survival benefit in patients with metastatic colorectal cancer in whom no standard therapy was effective.
LATE-BREAKING NEWS: FDA revokes Avastin breast cancer indication
The FDA has revoked its approval of the breast cancer indication for Avastin (bevacizumab). The anti-angiogenic therapy remains indicated for some colorectal, lung, brain, and kidney cancers.
- Loading...
Loading...
Loading... 
Loading...